353 related articles for article (PubMed ID: 35096550)
1. New translational and experimental insights into the role of pro-resolving lipid mediators in inflammatory bowel disease.
Pascoal LB; Palma BB; Chaim FHM; de Castro MM; Damázio TA; Franceschini APMF; Milanski M; Velloso LA; Leal RF
World J Exp Med; 2022 Jan; 12(1):1-15. PubMed ID: 35096550
[TBL] [Abstract][Full Text] [Related]
2. Possibility of averting cytokine storm in SARS-COV 2 patients using specialized pro-resolving lipid mediators.
Yasmeen N; Selvaraj H; Lakhawat SS; Datta M; Sharma PK; Jain A; Khanna R; Srinivasan J; Kumar V
Biochem Pharmacol; 2023 Mar; 209():115437. PubMed ID: 36731803
[TBL] [Abstract][Full Text] [Related]
3. Resolvins, Protectins, and Maresins: DHA-Derived Specialized Pro-Resolving Mediators, Biosynthetic Pathways, Synthetic Approaches, and Their Role in Inflammation.
Ferreira I; Falcato F; Bandarra N; Rauter AP
Molecules; 2022 Mar; 27(5):. PubMed ID: 35268778
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Changes in Lipid Mediator Profiling after Consumption of Specialized Pro-Resolving Lipid-Mediator-Enriched Marine Oil in Healthy Subjects.
Irún P; Carrera-Lasfuentes P; Sánchez-Luengo M; Belio Ú; Domper-Arnal MJ; Higuera GA; Hawkins M; de la Rosa X; Lanas A
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003333
[TBL] [Abstract][Full Text] [Related]
5. Resolution of Inflammation after Skeletal Muscle Ischemia-Reperfusion Injury: A Focus on the Lipid Mediators Lipoxins, Resolvins, Protectins and Maresins.
Barnig C; Lutzweiler G; Giannini M; Lejay A; Charles AL; Meyer A; Geny B
Antioxidants (Basel); 2022 Jun; 11(6):. PubMed ID: 35740110
[TBL] [Abstract][Full Text] [Related]
6. Pro-Resolving Lipid Mediators in the Pathophysiology of Asthma.
Kytikova O; Novgorodtseva T; Denisenko Y; Antonyuk M; Gvozdenko T
Medicina (Kaunas); 2019 Jun; 55(6):. PubMed ID: 31216723
[TBL] [Abstract][Full Text] [Related]
7. Regulation of T-Cell Immune Responses by Pro-Resolving Lipid Mediators.
Perez-Hernandez J; Chiurchiù V; Perruche S; You S
Front Immunol; 2021; 12():768133. PubMed ID: 34868025
[TBL] [Abstract][Full Text] [Related]
8. Developments of specialized pro-resolving mediators in periodontitis.
Liu YC
Hua Xi Kou Qiang Yi Xue Za Zhi; 2021 Feb; 39(1):94-98. PubMed ID: 33723943
[TBL] [Abstract][Full Text] [Related]
9. Specialized Pro-Resolving Lipid Mediators: The Future of Chronic Pain Therapy?
Chávez-Castillo M; Ortega Á; Cudris-Torres L; Duran P; Rojas M; Manzano A; Garrido B; Salazar J; Silva A; Rojas-Gomez DM; De Sanctis JB; Bermúdez V
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638711
[TBL] [Abstract][Full Text] [Related]
10. Actors and Factors in the Resolution of Intestinal Inflammation: Lipid Mediators As a New Approach to Therapy in Inflammatory Bowel Diseases.
Ungaro F; Rubbino F; Danese S; D'Alessio S
Front Immunol; 2017; 8():1331. PubMed ID: 29109724
[TBL] [Abstract][Full Text] [Related]
11. Omega-3 Polyunsaturated Fatty Acids in Critical Illness: Anti-Inflammatory, Proresolving, or Both?
Molfino A; Amabile MI; Monti M; Muscaritoli M
Oxid Med Cell Longev; 2017; 2017():5987082. PubMed ID: 28694914
[TBL] [Abstract][Full Text] [Related]
12. PCOS: A Chronic Disease That Fails to Produce Adequately Specialized Pro-Resolving Lipid Mediators (SPMs).
Regidor PA; de la Rosa X; Müller A; Mayr M; Gonzalez Santos F; Gracia Banzo R; Rizo JM
Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203665
[TBL] [Abstract][Full Text] [Related]
13. The Use of Specialized Pro-Resolving Mediators in Biomaterial-Based Immunomodulation.
Sousa AB; Barbosa JN
J Funct Biomater; 2023 Apr; 14(4):. PubMed ID: 37103313
[TBL] [Abstract][Full Text] [Related]
14. Specialized Pro-Resolving Mediators as Resolution Pharmacology for the Control of Pain and Itch.
Ji RR
Annu Rev Pharmacol Toxicol; 2023 Jan; 63():273-293. PubMed ID: 36100219
[TBL] [Abstract][Full Text] [Related]
15. Roles of Specialized Pro-Resolving Lipid Mediators in Autophagy and Inflammation.
Recchiuti A; Isopi E; Romano M; Mattoscio D
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32927853
[TBL] [Abstract][Full Text] [Related]
16. Specialized Proresolving Mediators for Therapeutic Interventions Targeting Metabolic and Inflammatory Disorders.
Han YH; Lee K; Saha A; Han J; Choi H; Noh M; Lee YH; Lee MO
Biomol Ther (Seoul); 2021 Sep; 29(5):455-464. PubMed ID: 34162770
[TBL] [Abstract][Full Text] [Related]
17. [Anti-inflammatory pro-resolving derivatives of omega-3 and omega-6 polyunsaturated fatty acids].
Nowak JZ
Postepy Hig Med Dosw (Online); 2010 Mar; 64():115-32. PubMed ID: 20354260
[TBL] [Abstract][Full Text] [Related]
18. Molecular Pharmacology of Inflammation Resolution in Atherosclerosis.
Kotlyarov S; Kotlyarova A
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563200
[TBL] [Abstract][Full Text] [Related]
19. Immuno-Resolving Ability of Resolvins, Protectins, and Maresins Derived from Omega-3 Fatty Acids in Metabolic Syndrome.
Kwon Y
Mol Nutr Food Res; 2020 Feb; 64(4):e1900824. PubMed ID: 31797565
[TBL] [Abstract][Full Text] [Related]
20. Profiling in resolving inflammatory exudates identifies novel anti-inflammatory and pro-resolving mediators and signals for termination.
J Intern Med; ; . PubMed ID: 20497301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
